Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI

British Journal of Clinical Pharmacology

Volumn 72, Issue 6, 2011, Pages 932-939

  Singh, Dave ^a   Collarini, Sara ^b   Poli, Gianluigi ^b   Acerbi, Daniela ^b   Amadasi, Alessio ^c   Rusca, Antonio ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Corporate Clinical Development Department ^*  (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d Cross Research SA   (Switzerland)

Author keywords

Beclometasone 17 monopropionate; Beclometasone dipropionate; Extra fine; Fixed combination; Formoterol; Spacer

Indexed keywords

ACTIVATED CARBON; BECLOMETASONE 17 MONOPROPIONATE; BECLOMETASONE DIPROPIONATE; DRUG METABOLITE; FORMOTEROL; FOSTER; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; HUMAN; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AREA UNDER CURVE; BECLOMETHASONE; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DRUG COMBINATIONS; ETHANOLAMINES; HUMANS; INHALATION SPACERS; LUNG; MALE; METERED DOSE INHALERS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 80855148139     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04024.x     Document Type: Article

References (34)

1. Global Initiative for Asthma (GINA). Available at (last accessed 18 January 2011).
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available at (last accessed 18 January 2011).
3. 2-agonist and corticosteroids. Eur Respir J 2002; 19: 182-91.
4. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-11.
5. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol 1999; 82: 383-9.
6. Van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54: 207-12.
7. Busse W, Koenig SM, Oppenheimer J, Sahn SA, Yancey SW, Reilly D, Edwards LD, Dorinsky PM. Steroid-sparing effects of fluticasone propionate 100μg and salmeterol 50μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250μg administered twice daily. J Allergy Clin Immunol 2003; 111: 57-65.
8. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170: 836-44.
9. Rabe K, Vermeire P, Soriano J, Maier W. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802-7.
10. Ganderton D, Lewis DA, Davies R, Meakin B, Brambilla G, Church T. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96: (Suppl. 1): S3-S8.
11. Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2007; 20: 290-303.
12. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009; 103: 41-9.
13. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl 1982; 119: 101-4.
14. Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest 1993; 104: 1332-7.
15. Newman SP, Weisz AW, Talee N, Clarke SW. Improvement of drug delivery with a breath-activated aerosol for patients with poor inhaler technique. Thorax 1991; 46: 712-6.
16. Lindgren S, Bake B, Larsson S. Clinical consequences of inadequate inhalation technique in asthma therapy. Eur J Respir Dis 1987; 70: 93-8.
17. Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet 2004; 43: 349-60.
18. Lavorini F, Fontana GA. Targeting drugs to the airways: the role of spacer devices. Expert Opin Drug Deliv 2009; 6: 91-102.
19. Bousquet J, Poli G, Acerbi D, Monno R, Ramael S, Nollevaux F. Systemic exposure and implications for lung deposition with an extra-fine HFA beclometasone dipropionate/formoterol fixed combination. Clin Pharmacokinet 2009; 48: 347-58.
20. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma or chronic obstructive pulmonary disease (COPD) in adults, and for use in the treatment of asthma in children and adolescents. 2009, Doc Ref. CPMP/EWP/4151/OO Rev.1 Available at (last accessed 18 January 2011).
21. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51: 400-9.
22. Boobis AR. Comparative physicochemical and pharmacokinetic profiles of inhaled beclometasone dipropionate and budesonide. Respir Med 1998; 92: (Suppl. B): 2-6.
23. Girodet PO, Molimard M. Pharmacological approach to evaluate aerosol pulmonary deposition. J Aerosol Med 2005; 18: 183-92.
24. Mulrennan S, Hogg JS, Teoh RC, Morice AH. Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone dipropionate. Br J Clin Pharmacol 2007; 63: 1365-2125.
25. Keller-Wood ME, Dallman MF. Corticosteroid inhibition of ACTH secretion. Endocr Rev 1984; 5: 1-24.
26. Derks MGM, van den Berg BTJ, van der Zee JS, Braat MCP, van Boxtel CJ. Biphasic effect-time courses in man after formoterol inhalation: eosinopenic and hypokalemic effects and inhibition of allergic skin reactions. J Pharmacol Exp Ther 1997; 283: 824-32.
27. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-6.
28. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994; 97: 29-37.
29. Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001; 6: 367-75.
30. Agertoft L, Laulund LW, Harrison LI, Pedersen S. Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol 2003; 35: 192-9.
31. De Backer W, De Volder A, Poli G, Acerbi D, Monno R, Herpich C, Brand P, Meyer T, Mariotti F. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic and COPD patients. J Aerosol Med Pulm. Drug Deliv 2010; 23: 137-48.
32. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 2005; 18: 379-85.
33. Dempsey OJ, Wilson AM, Coutie WJR, Lipworth BJ. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest 1999; 116: 935-40.
34. EMA guideline 'Guideline on Investigation of Bioequivalence', CPMP/EWP/QWP/1401/98 Rev. 1/ Corr, 20 January 2010.